Skip to main
HUM
HUM logo

Humana (HUM) Stock Forecast & Price Target

Humana (HUM) Analyst Ratings

Based on 16 analyst ratings
Hold
Strong Buy 6%
Buy 31%
Hold 63%
Sell 0%
Strong Sell 0%

Bulls say

Humana's financial outlook is bolstered by an increase in its 2025 EPS estimate to $17.06, reflecting strong second-quarter results and revised guidance. The company anticipates year-over-year earnings growth in 2027, driven by margin initiatives despite expectations of stable Stars performance. Additionally, Humana's commitment to environmental sustainability, exemplified by a greater than 20% reduction in greenhouse gas emissions since 2017, highlights its robust operational management and forward-thinking strategy.

Bears say

Humana's management predicts a slight decline in earnings per share (EPS) for 2026 compared to 2025, primarily due to challenges related to the Stars rating system, which are expected to be only partially mitigated by margin-enhancing initiatives. Additionally, there is concern that the company's FY27 EPS may fall short of estimates by approximately 10% due to the necessity for increased investments to support recovery in its Stars ratings. The anticipated competitive landscape suggests that, despite potential benefit cuts by peers, Humana may continue to face a significant benefit gap, potentially impacting its financial performance in an increasingly challenging environment.

Humana (HUM) has been analyzed by 16 analysts, with a consensus rating of Hold. 6% of analysts recommend a Strong Buy, 31% recommend Buy, 63% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humana (HUM) Forecast

Analysts have given Humana (HUM) a Hold based on their latest research and market trends.

According to 16 analysts, Humana (HUM) has a Hold consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $297.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $297.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humana (HUM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.